Rapid Molecular Test Developed for Enterovirus D68
By LabMedica International staff writers Posted on 02 Nov 2014 |
Image: Transmission electron micrograph (TEM) reveals some of the ultrastructural morphology exhibited by a grouping of Enterovirus virions (Photo courtesy of the Centers for Disease Control and Prevention).
A faster laboratory test has been developed to detect Enterovirus D68 (EV-D68) in specimens from people with respiratory illness.
Every year, enteroviruses and rhinoviruses cause millions of respiratory illnesses in children and this year, EV-D68 has been the most common type of Enterovirus identified, leading to increases in illnesses among children and affecting those with asthma most severely.
Scientists at the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed a real-time reverse transcription polymerase chain reaction, (rRT-PCR), and it identifies all strains of EV-D68 that have been seen this summer and fall. The new test has fewer and shorter steps than the test that the CDC and some US states were using for the EV-D68 outbreak and the new test allows for more specimens to be tested at the same time.
The CDC has tested 1,163 specimens submitted by hospitals and from 45 US states. Of the specimens tested by the CDC laboratory from August 1, 2014, to October 10, 2014, about half have tested positive for EV-D68. About one third have tested positive for a rhinovirus or an Enterovirus other than EV-D68. The new laboratory test will allow the CDC to process the approximately one-thousand remaining specimens at a much faster rate. The most suitable specimens are nasopharyngeal and/or oropharyngeal swab which give a high diagnostic yield or other respiratory specimens such as nasal wash or aspirates. Serum specimens have an expected low yield.
Viral ribonucleic acid (RNA) is extracted using QIAamp Viral RNA Mini Kit (Qiagen; Valencia, CA, USA) and the rRT-PCR was performed using the SuperScript III Platinum One Step qRT PCR Kit (Invitrogen; Carlsbad, CA, USA) and the AB 7500 Real Time PCR Systems (Applied Biosystems; Foster City, CA, USA). The CDC expects to complete testing of the remaining specimens that were received since mid-September within about 7 to 10 days; going from testing about 40 specimens per day to testing up to 180 per day. This will allow them to then test and report results for new specimens within a few days of receiving them.
The outcome of the EV-D68 test is to collect surveillance data to help public health officials target the responses to the outbreak, and not to determine the treatment plan for a specific patient. The CDC prioritized testing for the most severe cases since the outbreak began in August 2014 to get a better understanding of the disease.
Related Links:
US Centers for Disease Control and Prevention
Qiagen
Invitrogen
Every year, enteroviruses and rhinoviruses cause millions of respiratory illnesses in children and this year, EV-D68 has been the most common type of Enterovirus identified, leading to increases in illnesses among children and affecting those with asthma most severely.
Scientists at the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) developed a real-time reverse transcription polymerase chain reaction, (rRT-PCR), and it identifies all strains of EV-D68 that have been seen this summer and fall. The new test has fewer and shorter steps than the test that the CDC and some US states were using for the EV-D68 outbreak and the new test allows for more specimens to be tested at the same time.
The CDC has tested 1,163 specimens submitted by hospitals and from 45 US states. Of the specimens tested by the CDC laboratory from August 1, 2014, to October 10, 2014, about half have tested positive for EV-D68. About one third have tested positive for a rhinovirus or an Enterovirus other than EV-D68. The new laboratory test will allow the CDC to process the approximately one-thousand remaining specimens at a much faster rate. The most suitable specimens are nasopharyngeal and/or oropharyngeal swab which give a high diagnostic yield or other respiratory specimens such as nasal wash or aspirates. Serum specimens have an expected low yield.
Viral ribonucleic acid (RNA) is extracted using QIAamp Viral RNA Mini Kit (Qiagen; Valencia, CA, USA) and the rRT-PCR was performed using the SuperScript III Platinum One Step qRT PCR Kit (Invitrogen; Carlsbad, CA, USA) and the AB 7500 Real Time PCR Systems (Applied Biosystems; Foster City, CA, USA). The CDC expects to complete testing of the remaining specimens that were received since mid-September within about 7 to 10 days; going from testing about 40 specimens per day to testing up to 180 per day. This will allow them to then test and report results for new specimens within a few days of receiving them.
The outcome of the EV-D68 test is to collect surveillance data to help public health officials target the responses to the outbreak, and not to determine the treatment plan for a specific patient. The CDC prioritized testing for the most severe cases since the outbreak began in August 2014 to get a better understanding of the disease.
Related Links:
US Centers for Disease Control and Prevention
Qiagen
Invitrogen
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia